2Kwan P, Sander JW. The natural history of epilepsy: an epidemio|ogical view. J Neurol Neurosurg Psychiatry, 2004, 75: 1376-1381.
3Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med, 2000, 342: 314-319.
4Picot MC, Baldy-Moulinier M, Dauris JP, et al. The prevalence of epilepsy and pharmaeoresistant epilepsy in adults : a population- based study in a Western European country. Epilepsia, 2008,49 : 1230-1238.
5Fisher RS, van Emde Boas WE, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia, 2005, 46: 470472.
6Glauser T,Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia, 2006, 47 : 1094-1120.
7Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre raudomised double- blind study. Vigabatrin European Monotherapy Study Group. Lancet, 1999, 354:13-19.
8Marson AG, A1-Kharusi AM, Alwaidh M, et M. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled triM. Lancet, 2007, 369 : 1000- 1015.
9Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy : response to sequential treatment schedules. Eur J Neurol, 2006, 13 : 277-282.
10Arts WF, Brouwer OF, Peters AC, et al. Course and prognosis of childhood epilepsy : 5-year follow-up of the Dutch study of epilepsy in childhood. Brain, 2004, 127 ( Pt 8) : 1774-1784.
